KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $2.2 billion.

  • Halozyme Therapeutics' Liabilities and Shareholders Equity rose 4.87% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 billion, marking a year-over-year increase of 11.39%. This contributed to the annual value of $2.1 billion for FY2024, which is 19.05% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Liabilities and Shareholders Equity of $2.2 billion as of Q3 2025, which was up 8.15% from $2.1 billion recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Liabilities and Shareholders Equity peaked at $2.2 billion during Q3 2025, and registered a low of $966.6 million during Q1 2021.
  • In the last 3 years, Halozyme Therapeutics' Liabilities and Shareholders Equity had a median value of $2.0 billion in 2024 and averaged $2.0 billion.
  • As far as peak fluctuations go, Halozyme Therapeutics' Liabilities and Shareholders Equity skyrocketed by 126.21% in 2021, and later dropped by 5.88% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $1.1 billion in 2021, then skyrocketed by 66.74% to $1.8 billion in 2022, then fell by 5.88% to $1.7 billion in 2023, then climbed by 19.05% to $2.1 billion in 2024, then rose by 4.87% to $2.2 billion in 2025.
  • Its Liabilities and Shareholders Equity was $2.2 billion in Q3 2025, compared to $2.1 billion in Q2 2025 and $2.2 billion in Q1 2025.